FDA approves Bristol-Myers' Opdivo for small cell lung cancer [Reuters (UK)]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Reuters
FDA approves Bristol-Myers' Opdivo for small cell lung cancer | Reuters Reuters Staff 1 Min Read (Reuters) - Bristol-Myers Squibb Co said on Friday the U.S. Food and Drug Administration approved its treatment, Opdivo, for patients whose lung cancer had progressed even after undergoing chemotherapy and at least one other therapy. The drug competes with Merck & Co’s Keytruda and belongs to a class of treatments that work by activating the immune system to attack tumors. Both treatments have racked up approvals for indications, including melanoma, lung cancer and head and neck cancer. Sales of both the drugs are neck and neck, with Opdivo generating $1.63 billion in the second quarter and Keytruda $1.67 billion. Bristol-Myers said Opdivo is the first immunooncology treatment approved for patients with small cell lung cancer, which accounts for about 10 to 15 percent of all lung cancers. Bristol-Myers shares rose 0.5 percent to $61.40 in premarket trading. Reporting by Aakash Jagadeesh Ba
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Earnings Preview: Bristol Myers Squibb (BMY) Q1 Earnings Expected to Decline [Yahoo! Finance]Yahoo! Finance
- Bristol-Myers Squibb (NYSE: BMY) had its price target raised by analysts at Wells Fargo & Company from $51.00 to $52.00. They now have an "equal weight" rating on the stock.MarketBeat
- Pathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into Clinic [Yahoo! Finance]Yahoo! Finance
- Bristol-Myers Squibb: Market Pessimism Won't Last Forever [Seeking Alpha]Seeking Alpha
- 2 High-Yield Dividend Stocks to Buy and Hold for 10 Years [Yahoo! Finance]Yahoo! Finance
BMY
Earnings
- 2/2/24 - Beat
BMY
Sec Filings
- 4/2/24 - Form 4
- 4/2/24 - Form 4
- 4/2/24 - Form 4
- BMY's page on the SEC website